<DOC>
	<DOCNO>NCT00535015</DOCNO>
	<brief_summary>The purpose study determine whether Betamarc effective improve appetite reverse weight loss patient advance Non-Small Cell Lung Cancer .</brief_summary>
	<brief_title>Safety Efficacy Study Betamarc Treat Loss Weight Appetite Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<criteria>Newly diagnose Stage IIIB IV nonresectable NSCLC . Recurrent disease resection earlier stage disease acceptable long patient least 6 month surgery . Treatment plan include platinumbased doublet chemotherapy . ECOG 0 , 1 2 . Selfreported loss body weight anorexia . Serum Creactive protein â‰¥5 mg/L . Life expectancy least 6 month . Adequate bone marrow , liver renal function . Normal serum potassium . Ability comply study requirement give write informed consent . Known physical functional obstruction gastrointestinal tract , malabsorption , intractable vomiting , uncontrollable diarrhea , concurrently receive tube feed parenteral nutrition , unable swallow investigational drug product . Concomitant therapy appetite stimulant . History poorly control hypertension congestive heart failure . Any implanted device could interfere DXA scan . Prolongation QT interval . History additional risk factor torsades de pointe . Concomitant therapy betaadrenergic receptor antagonist ( betablockers ) ergot derivative . Females breast feeding , pregnant childbearing potential use adequate birth control . Any second malignancy might confound interpretation safety efficacy assessment . Any condition increase patient 's risk participating study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>